Regular Article
Inhibition of Inflammation-Induced Thermal Hypersensitivity by Sumatriptan through Activation of 5-HT1B/1D Receptors

https://doi.org/10.1006/exnr.2000.7521Get rights and content

Abstract

Migraine is effectively treated by drugs acting via 5-HT1B/1D receptors; however, the antinociceptive effects of such agents have not been fully investigated, particularly in models in which sensitization may be present. The aim of these studies was to evaluate the effects of the 5-HT1B/1D receptor agonist sumatriptan in specific models of pain states: a mouse model of inflammation-induced thermal hyperalgesia and a rat model of nerve injury-induced thermal hyperalgesia. In female mice, following intraplantar injection of carrageenan 225 min earlier, sumatriptan (300 μg/kg intraperitoneally; ip) increased paw withdrawal latency (PWL) from 3.1 ± 0.4 s in the saline group to 5.6 ± 0.9 s, measured 240 min postcarrageenan (P < 0.05 ANOVA followed by post hoc Dunnett's test). A similar effect was seen in male mice. Sumatriptan was also effective in male mice when given ip and subcutaneously 15 min precarrageenan, with a maximum effect at 30 μg/kg (ip latency 7.4 ± 1.3 s compared to saline group, 2.6 ± 0.7 s; iv latency 5.9 ± 0.8 s compared to saline group, 2.9 ± 0.3 s; P < 0.05 ANOVA followed by post hoc Dunnett's test). The number of mice required to give a response that could be reliably attributed to sumatriptan (number needed to treat) was calculated using discriminant analysis and found to be 2.6. The ability of sumatriptan to attenuate the carrageenan-induced reduction in PWL was blocked by the mixed 5-HT1B/1D receptor antagonist GR-127935 (3 mg/kg ip) but not by the 5-HT1B receptor antagonist SB-224289 (10 mg/kg ip). Sumatriptan had no effect on thermal hyperalgesia induced by sciatic nerve ligation in the rat at any time point. These data demonstrate that sumatriptan attenuates the hypersensitivity to noxious thermal stimuli induced by intraplantar carrageenan.

References (54)

  • L.C. Stanfa et al.

    Amplification of spinal nociceptive transmission depends on the generation of nitric oxide in normal and carrageenan rats

    Brain Res.

    (1996)
  • S. Wakisaka et al.

    Effects of peripheral nerve injuries and tissue inflammation on the levels of neuropeptide Y-like immunoreactivity in rat primary afferent neurons

    Brain Res.

    (1992)
  • D.J. Williamson et al.

    The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation

    Eur. J. Pharmacol.

    (1997)
  • L. Arvieu et al.

    Sumatriptan inhibits the release of CGRP and substance P from the rat spinal cord

    NeuroReport

    (1996)
  • L. Bendtsen et al.

    Decreased pain detection and tolerance thresholds in chronic tension-type headache

    Arch. Neurol.

    (1996)
  • R. Burstein et al.

    Parasympathetic contributions to peripheral and central sensitisation during migraine

    Neuroscience

    (1999)
  • R. Burstein et al.

    Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons

    J. Neurophysiol.

    (1998)
  • M.G. Buzzi et al.

    The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater

    Br. J. Pharmacol.

    (1990)
  • J.J. Chen et al.

    Multiple subtypes of serotonin receptors are expressed in rat sensory neurons in culture

    J. Pharmacol. Exp. Ther.

    (1998)
  • J.W. Clitherow et al.

    Evolution of a novel series of [(n,n-dimethylamino)propyl]- and piperazinylbenzanilides as the first selective 5-HT1D antagonists

    J. Med. Chem.

    (1994)
  • H.E. Connor et al.

    Naratriptan—Biological profile in animal models relevant to migraine

    Cephalalgia

    (1997)
  • H.E. Connor et al.

    Characterization of 5-HT receptors mediating contraction of canine and primate basilar artery by use of GR43175, a selective 5-HT 1-like receptor agonist

    Br. J. Pharmacol.

    (1989)
  • M.J. Cumberbatch et al.

    Differential effects of the 5HT(1B/1D) receptor agonist naratriptan on trigeminal versus spinal nociceptive responses

    Cephalalgia

    (1998)
  • Ellrich, J, and, K. Messlinger, 1999, Central effects of the anti-migraine drug naratriptan in a rat model of meningeal...
  • M.D Ferrari

    Sumatriptan in the treatment of migraine

    Neurology

    (1993)
  • C. Ghelardini et al.

    Prevention by sumatriptan of hyperalgesia induced by morphine withdrawal

    Fundam. Clin. Pharmacol.

    (1996)
  • Cited by (44)

    • Sumatriptan alleviates radiation-induced oral mucositis in rats by inhibition of NF-kB and ERK activation, prevention of TNF-α and ROS release

      2020, Archives of Oral Biology
      Citation Excerpt :

      Sumatriptan is a safe drug and lacks the side effects of other anti-inflammatory drugs. Previous studies using 5-HT receptors antagonist showed that sumatriptan acts through 5HT1B/D presynaptic autoreceptors to attenuate the inflammation (Bingham et al., 2001; Dehdashtian et al., 2019; Haddadi et al., 2018; Pierce, Xie, Peroutka, & Levine, 1996; Sheibani et al., 2019). It also prevents the activation of NF-kB and the release of IL-1β, TNF-α and other inflammatory cytokines, protects against apoptosis and enhances endogenous anti-oxidants (Dejban, Rahimi, Takzare, Jahansouz, & Dehpour, 2019; Khalilzadeh et al., 2018).

    • Serotonin type-1D receptor stimulation of A-type K<sup>+</sup> channel decreases membrane excitability through the protein kinase A- and B-Raf-dependent p38 MAPK pathways in mouse trigeminal ganglion neurons

      2016, Cellular Signalling
      Citation Excerpt :

      In addition to this central nervous system action, triptans also attenuate pain-related behaviors in rodent models of somatic and visceral pain, as well as in models of resistant trigeminal neuralgia and peripheral neuropathic pain [14–15]. For example, 5-HT1B/1D agonists significantly attenuate neurogenic inflammation [16] and hyperalgesia [15,17]. In addition, clinically effective anti-migraine agents, including zolmitriptan and SUMA, attenuated the hyper-responsiveness in response to mechanical stimulation of the face in a rat model of trigeminal neuropathic pain [14].

    View all citing articles on Scopus
    View full text